INBX
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc historical holders
total: 2
Viking Global Investors Inhibrx Biosciences, Inc transactions over time
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 2
- Reduced:
- 2
- Held since:
- 2020 Q3
- Held for:
- 23 quarters
- Latest activity:
- 2025 Q4
Ole Andreas Halvorsen has been an institutional investor in Inhibrx Biosciences, Inc (INBX) since 2020 Q3. According to 2026 Q1 report, Ole Andreas Halvorsen holds 1,437,705 shares with a market value of roughly $96.66M representing 0.27% of their equity portfolio. The fund/company first acquired INBX in 2020 Q3, initially purchasing about 5.31M shares. Since the initial investment, Viking Global Investors has made 4 more transactions in this position.
Does Ole Andreas Halvorsen still hold INBX?
Yes, Ole Andreas Halvorsen continues to hold Inhibrx Biosciences, Inc (INBX). According to their 2026 Q1 report, they maintain a position of 1,437,705 shares valued at approximately $96.66M, representing 0.27% of their equity portfolio.
When did Ole Andreas Halvorsen first invest in INBX?
Ole Andreas Halvorsen first invested in Inhibrx Biosciences, Inc (INBX) in 2020 Q3 at the reported quarter-end price of $18.00 per share, acquiring 5,305,866 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for INBX?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Inhibrx Biosciences, Inc (INBX) is approximately $19.26 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $19.26
- Weighted AVG sell price:
- $18.14
INBX transactions history by Viking Global Investors
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
0.30%
|
1,437,705
|
$79.00
|
$113,578,695
|
-19.58% (-350,000)
|
-0.07%
|
|
2024 Q2
|
0.10%
|
1,787,705
|
$14.17
|
$25,331,780
|
-75.00% (-5,363,121)
|
-0.28%
|
|
2023 Q3
|
0.53%
|
7,150,826
|
$18.35
|
$131,217,657
|
+7.71% (+511,627)
|
+0.04%
|
|
2022 Q4
|
0.82%
|
6,639,199
|
$24.64
|
$163,589,863
|
+25.13% (+1,333,333)
|
+0.16%
|
|
2020 Q3
|
0.35%
|
$18.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.